10-Q: OSR Holdings Reports Q3 Loss Amid Strategic Shifts

OSR Holdings, Inc. reported increased operating and net losses for the nine months ended September 30, 2025, driven by public company costs and merger expenses, while announcing a strategic acquisition and ongoing capital raises.

Summary

• Net sales for the three months ended September 30, 2025, decreased by 24% to $627,747 from $822,996 in the prior year, primarily due to a shift in RMC's contractual arrangement to a consignment-based model.
• Gross profit for the three months ended September 30, 2025, increased by 46% to $261,734, up from $179,093, despite lower sales, due to reduced cost of sales under the new consignment model.
• Operating loss for the three months ended September 30, 2025, increased by 7% to $(3,803,465) from $(3,566,542) in the prior year.
• Net loss for the three months ended September 30, 2025, was $(3,194,874), a slight improvement from $(3,356,533) in the prior year.
• For the nine months ended September 30, 2025, net sales decreased by 3% to $2,524,536, and gross profit decreased by 29% to $463,201.
• Operating loss for the nine months ended September 30, 2025, increased by 19% to $(11,950,469) from $(10,079,178) in the prior year.
• Net loss for the nine months ended September 30, 2025, significantly increased by 120% to $(19,812,886) from $(8,989,387) in the prior year, largely due to $8.5 million in one-time merger-related expenses.
• Selling, General and Administrative (SG&A) expenses increased by 9% for the three months and 16% for the nine months ended September 30, 2025, primarily due to public company obligations and personnel costs following the February 14, 2025 Business Combination.
• Cash and cash equivalents increased to $2,177,309 as of September 30, 2025, from $341,543 at December 31, 2024, supported by financing activities.
• The company received a Nasdaq minimum bid price deficiency notice on September 5, 2025, and has until March 4, 2026, to regain compliance.
• The Board of Directors approved the acquisition of Woori IO Co.,Ltd., a Korean medical-device company, through a share exchange valued at approximately $10.5 million, with potential for conversion into OSRH common stock.
• The company continues to incur significant operating losses and had an accumulated deficit of approximately $32.33 million as of September 30, 2025.
• Ongoing capital raising efforts include an Equity Line of Credit (ELOC) agreement for up to $80 million and the issuance of warrants and convertible notes.

Sentiment

Score: 3

Explanation: The company's financial performance for the nine months ended September 30, 2025, shows significant deterioration in net loss and operating loss, coupled with increased cash burn from operations. The Nasdaq bid price deficiency notice is a major concern. While strategic acquisitions and capital raising efforts are underway, they are reactive to the company's financial needs and market challenges. The overall sentiment is negative due to poor financial results and listing uncertainty, despite some positive strategic developments.

Positives

• Gross profit for the three months ended September 30, 2025, increased by 46% to $261,734, driven by a more profitable consignment-based model for RMC.
• Basic loss per ordinary share significantly improved to $(0.10) for the three months and $(0.76) for the nine months ended September 30, 2025, compared to $(1.56) and $(4.17) respectively in the prior year, likely due to a higher number of outstanding shares post-merger.
• Cash and cash equivalents increased substantially to $2,177,309 as of September 30, 2025, from $341,543 at December 31, 2024, indicating successful capital raising efforts.
• The acquisition of Woori IO Co.,Ltd. is a strategic move to expand the medical device portfolio, particularly in noninvasive glucose monitoring and biosensing technologies.
• The company has secured an Equity Line of Credit (ELOC) for up to $80 million and other financing instruments, providing access to capital for ongoing operations.

Negatives

• Net sales for the three months ended September 30, 2025, decreased by 24% to $627,747.
• Net sales for the nine months ended September 30, 2025, decreased by 3% to $2,524,536.
• Gross profit for the nine months ended September 30, 2025, decreased by 29% to $463,201.
• Operating loss increased by 7% for the three months and 19% for the nine months ended September 30, 2025.
• Net loss for the nine months ended September 30, 2025, increased significantly by 120% to $(19,812,886).
• Selling, General and Administrative (SG&A) expenses increased by 9% for the three months and 16% for the nine months, reflecting higher costs associated with public company operations.
• Other expenses for the nine months ended September 30, 2025, increased by $9,133,977, primarily due to $8.5 million in one-time merger-related expenses.
• The company received a Nasdaq minimum bid price deficiency notice, indicating its stock price fell below $1.00 for 30 consecutive business days, posing a risk to its listing.
• Accumulated deficit increased to approximately $32.33 million as of September 30, 2025, highlighting ongoing unprofitability.
• Net cash used in operating activities increased to $(3,258,041) for the nine months ended September 30, 2025, from $(1,668,444) in the prior year, indicating higher cash burn from operations.

Risks

• The company received a Nasdaq minimum bid price deficiency notice and must regain compliance by March 4, 2026, or face delisting.
• The company has incurred significant operating losses and negative cash flows from operating activities since inception, with an accumulated deficit of $32.33 million as of September 30, 2025.
• Future operations are dependent on securing additional capital through financing initiatives like the ELOC, warrants, and notes, which may not always be available or on favorable terms.
• The issuance of common stock under the ELOC, warrants, and convertible notes may have a significantly dilutive effect on existing shareholders.
• The company is subject to ongoing legal proceedings, including a civil action for $425,000 in brokerage fees and a breach of contract complaint from Chardan Capital Markets, LLC, which could result in damages or other liabilities.
• The company's R&D expenses are expected to increase significantly in 2026, from $2.5 million-$3.0 million per quarter to potentially $5.0 million-$6.0 million per quarter, which will further impact cash flow and profitability.
• The company's ability to maintain its listing on Nasdaq is crucial, and failure to do so could adversely affect its stock price and access to capital markets.
• The company operates in South Korea, Switzerland, and Germany, exposing it to currency risk due to foreign currency translation.

Future Outlook

Management expects R&D expenses to increase significantly, ranging from $2.5 million to $3.0 million per quarter beginning in 2026, potentially rising to $5.0 million to $6.0 million per quarter. The company intends to leverage OSRH's governance, global partnerships, and clinical development resources to accelerate product development and commercialization for newly acquired entities like Woori IO Co.,Ltd. Management is actively monitoring its share price to regain Nasdaq compliance by March 4, 2026, and plans to utilize the ELOC and other financing instruments to secure additional capital.

Management Comments

• Management expects the consignment-based model for RMC to enhance gross-margin stability in future periods.
• The decline in gross profit for the nine-month period was primarily due to the impact of the second quarter, during which RMC sold previously held inventory back to the supplier at cost as part of the transition to the new consignment-based model. This transaction temporarily depressed gross margin in the second quarter, offsetting the margin improvement realized in the third quarter. The margin decline in the second quarter was a one-time event.
• Management is actively monitoring the company's share price performance and evaluating various available options to regain Nasdaq compliance within the applicable period, which may include corporate or capital structure adjustments, enhanced investor communications, and other strategic measures as appropriate.
• The company intends to take all necessary actions to maintain its continued listing on the Nasdaq Capital Market.

Industry Context

OSR Holdings operates in the global healthcare sector, specifically in biotech (oral immunotherapies for cancer, design-augmented biologics for degenerative diseases) and medical device distribution (neurovascular intervention, noninvasive glucose monitoring). The acquisition of Woori IO Co.,Ltd. aligns with the company's vision to acquire and operate innovative healthcare-related companies globally, expanding its medical device portfolio into biosensing technologies. The significant R&D expenditure plans for 2026 indicate a commitment to innovation, which is typical for biotech and medical device companies, but also highlights the capital-intensive nature of the industry.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• A civil action filed by Benjamin Securities, Inc. against the company in Supreme Court, New York County, seeking $425,000.00 in brokerage fees and costs, remains pending as of September 30, 2025.
• Chardan Capital Markets, LLC filed a complaint on September 2, 2025, in the U.S. District Court for the Southern District of New York against the company and Kuk Hyoun Hwang, asserting claims for breach of contract and related causes of action. The matter is in early discovery stages, with a status conference scheduled for January 8, 2026.

Related Party Transactions

• The company has short-term borrowings from BCM Europe AG (major shareholder) totaling $860,000 at 3.00% interest as of September 30, 2025.
• The company has short-term borrowings from Bellevue Global Life Sciences Acquisition Corp (other related party) totaling $1,278,000 at 0% interest as of September 30, 2025.
• The company pays a monthly fee of $7,500 to an affiliate of Bellevue Capital Management, LLC (ultimate parent entity) for office space, utilities, and administrative support, which began March 1, 2023.
• Compensations paid or accrued to key management of the Parent for the nine months ended September 30, 2025, were $461,498, compared to $283,050 in the prior year.

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from ongoing and future capital raises (ELOC, warrants, convertible notes) and the Woori IO acquisition. The Nasdaq bid price deficiency notice poses a risk of delisting, which could negatively impact share liquidity and value. Increased operating losses and accumulated deficit indicate continued unprofitability.
• **Employees**: Increased personnel-related expenses (salaries, severance, benefits) suggest continued investment in human capital, potentially benefiting employees.
• **Customers**: The acquisition of Woori IO Co.,Ltd. aims to accelerate product development and commercialization, potentially leading to new and enhanced medical devices, particularly in noninvasive glucose monitoring, which could benefit customers.
• **Creditors**: The company's reliance on borrowings and convertible notes, along with increased liabilities, indicates higher financial leverage. The senior secured nature of some convertible notes provides a degree of protection for those specific creditors.
• **Suppliers**: The shift to a consignment-based model for RMC's major supplier could alter payment terms and inventory management for that specific supplier, potentially impacting their cash flow or risk exposure.

Next Steps

• Regain compliance with Nasdaq Listing Rule 5550(a)(2) by maintaining a closing bid price of at least $1.00 for ten consecutive business days by March 4, 2026.
• Integrate Woori IO Co.,Ltd. into OSRK and leverage OSRH's resources to accelerate product development and commercialization.
• Continue utilizing the Equity Line of Credit (ELOC) and other available financing instruments to secure additional capital for ongoing operations.
• Proceed with the early discovery stages and status conference for the legal complaint filed by Chardan Capital Markets, LLC on January 8, 2026.
• Manage increasing R&D expenses, projected to be $2.5 million to $3.0 million per quarter in 2026, potentially rising to $5.0 million to $6.0 million per quarter.

Key Dates

Recommendation

The company's financial performance for the nine months ended September 30, 2025, is severely negative, with a 120% increase in net loss and a 19% increase in operating loss. The accumulated deficit has grown significantly. A Nasdaq minimum bid price deficiency notice indicates a serious risk of delisting, which would severely impair liquidity and investor confidence. While strategic acquisitions like Woori IO Co.,Ltd. and ongoing capital raises provide some future potential and immediate liquidity, they are reactive measures to a challenging financial position and come with substantial dilution for existing shareholders. The presence of multiple legal proceedings adds further uncertainty and potential liabilities. The combination of poor financial results, delisting risk, and significant dilution makes OSR Holdings a high-risk investment with a strong negative outlook.

Keywords

Healthcare, Biotech, Medical Devices, SEC Filing, 10-Q, Financial Results, Nasdaq Listing, Capital Raise, Acquisition, Corporate Governance, Risk Factors, OSR Holdings